Belushi, Savient observe Gout Awareness Day

Share this article:

Today is Gout Awareness Day, and Jim Belushi is speaking out about his experiences with the disease.

The actor, who has had the rheumatic disease for around 15 years, chaired a roundtable with three other patients talking about living with the disease. The talk was posted to patient community site CreakyJoints, one of several supported by the non-profit Global Healthy Living Foundation. The presentation was supported by Krystexxa maker Savient Pharmaceuticals.

The informational effort includes a rheumatologist locator on the website, and visitors are encouraged to Tweet their experiences with gout using the #notjustgout hashtag (at press time, it hadn't gotten much traction).  

The Centers for Disease Control estimates around 3 million adults had the condition as of 2005. More men than women experience gout and African American men are twice as likely as white men to have the condition, which has three general stages: asymptomatic, in which monosodium urate crystals build up in tissue; acute flares, which the CDC says can be “mild or excruciating”; and chronic arthritis. A metabolic disorder sets the crystal buildup in motion, and the disease is closely associated with an increased kidney stone risk.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.